Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

International Journal of Molecular Sciences – August 2023

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study